

10667188

=> d his

(FILE 'HOME' ENTERED AT 11:48:25 ON 19 JUN 2004)

FILE 'REGISTRY' ENTERED AT 11:48:39 ON 19 JUN 2004

L1 STRUCTURE UPLOADED

L2 3 S L1

L3 46 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 11:49:31 ON 19 JUN 2004

L4 3 S L3

FILE 'BEILSTEIN' ENTERED AT 11:51:12 ON 19 JUN 2004


L5 0 S L1

L6 0 S L1 SSS FULL

=> d l1

L1 HAS NO ANSWERS

L1 STR




10667188

1-3 bib abs hitstr

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:267332 CAPLUS
DN 140:303670
TI Preparation of imidazopyridines as 5-HT4 receptor agonists
IN Iguchi, Satoru; Katsu, Yasuhiro; Kon-I, Kana; Noguchi, Hirohide; Uchida, Chikara
PA Pfizer Pharmaceuticals Inc., Japan; Pfizer Inc.
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004026869	A1	20040401	WO 2003-IB3971	20030908
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2002-412485P	P	20020920		
OS	MARPAT 140:303670				
GI					



I

AB The title compds. [I; R1 = H, halo; R2 = Me, Et; R3 = branched alkyl or alkyl substituted by alkoxy; with the proviso that when the terminal carbon atom of said alkyl group is substituted by said alkoxy group, said alkyl group is a branched alkyl group] which have 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans, were prepared. E.g., a 6-step synthesis of I [R1 = Cl; R2 = Me; R3 = iso-Bu] which showed Ki of 0.82 nM against 5-HT4 binding, was given. This invention also provides a pharmaceutical composition comprising the compound I.


IT 519148-48-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of imidazopyridinecarboxamides as 5-HT4 receptor agonists)

RN 519148-48-2 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-methyl-N-[[1-(2-methylpropyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

10667188




IT 519148-50-6P 519148-51-7P 519148-52-8P
519148-53-9P 676322-47-7P 676322-48-8P
676322-49-9P 676322-50-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of imidazopyridinecarboxamides as 5-HT4 receptor agonists)

RN 519148-50-6 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-2-methyl-N-[[1-(2-
methylpropyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 519148-51-7 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(3,3-
dimethylbutyl)-4-piperidinyl]methyl]-2-ethyl- (9CI) (CA INDEX NAME)

10667188




RN 519148-52-8 CAPLUS
 CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[[1-(2-methoxy-2-methylpropyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 519148-53-9 CAPLUS
 CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(2-methoxy-2-methylpropyl)-4-piperidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)

10667188




RN 676322-47-7 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(2,2-dimethylpropyl)-4-piperidiny]methyl]-2-ethyl- (9CI) (CA INDEX NAME)



RN 676322-48-8 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(2,2-dimethylpropyl)-4-piperidiny]methyl]-2-methyl- (9CI) (CA INDEX NAME)



10667188


RN 676322-49-9 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(3-methoxy-3-methylbutyl)-4-piperidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 676322-50-2 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(3-methoxy-2,2-dimethylpropyl)-4-piperidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)




IT 519147-99-0P 676322-53-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazopyridinecarboxamides as 5-HT4 receptor agonists)


RN 519147-99-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(5-amino-6-chloro-2-ethylimidazo[1,2-a]pyridin-8-yl)carbonyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10667188



RN 676322-53-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[[(5-amino-6-chloro-2-methylimidazo[1,2-a]pyridin-8-yl)carbonyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:267331 CAPLUS
 DN 140:303669
 TI Preparation of N-(piperidin-4-ylmethyl) imidazopyridinecarboxamides as 5-HT4 receptor modulators
 IN Katsu, Yasuhiro; Kon-I, Kana; Morita, Mikio; Noguchi, Hirohide; Uchida, Chikara
 PA Pfizer Pharmaceuticals Inc., Japan; Pfizer Inc.
 SO PCT Int. Appl., 74 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026868	A1	20040401	WO 2003-IB3945	20030908

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,


10667188

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-412426P P 20020920

OS MARPAT 140:303669

GI




AB The title compds. [I; R1 = H, halo; R2 = H, alkyl, aminocarbonyl, mono- or dialkylaminocarbonyl; R3 = alkyl which is substituted by at least one substituent selected from the group consisting of substituents α ; said substituents α = aryl, OH, oxo, heterocyclyl, etc.] which have 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans, were prepared. E.g., a multi-step synthesis of I [R1 = Cl; R2 = H; R3 = 3,3-dimethyl-2-oxobutyl], starting from Et 6-[(2,2,-dimethylpropanoyl)amino]-2-fluoronicotinate, was given. All compds. I prepared in the working examples showed Ki of 0.19 nM to 47 nM with respect to the affinity to the 5-HT4 receptor. This invention also provides a pharmaceutical composition comprising the compound I.

IT 676351-57-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of N-(piperidin-4-ylmethyl) imidazopyridinecarboxamides as 5-HT4 receptor modulators)

RN 676351-57-8 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(3,3-dimethyl-2-oxobutyl)-4-piperidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



IT 676351-58-9P 676351-59-0P 676351-60-3P
676351-61-4P 676351-62-5P 676351-63-6P

10667188


676351-64-7P 676351-65-8P 676351-66-9P
676351-67-0P 676351-68-1P 676351-69-2P
676351-70-5P 676351-71-6P 676351-72-7P
676351-73-8P 676351-74-9P 676351-75-0P
676351-76-1P 676351-77-2P 676351-78-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of N-(piperidin-4-ylmethyl) imidazopyridinecarboxamides as
5-HT₄ receptor modulators)


RN 676351-58-9 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[[1-(3,3-dimethyl-2-
oxobutyl)-4-piperidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 676351-59-0 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(3,3-dimethyl-
2-oxobutyl)-4-piperidinyl]methyl]-2-ethyl- (9CI) (CA INDEX NAME)



RN 676351-60-3 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[[1-(3-
hydroxy-3-methyl-2-oxobutyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

10667188



RN 676351-61-4 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[[1-(4-hydroxy-3,3-dimethyl-2-oxobutyl)-4-piperidiny]methyl]- (9CI) (CA INDEX NAME)




RN 676351-62-5 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[[1-[2-oxo-2-(1-piperidiny)ethyl]-4-piperidiny]methyl]- (9CI) (CA INDEX NAME)

10667188

PAGE 1-A




PAGE 2-A




RN 676351-63-6 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[[1-[2-(4-morpholinyl)-2-oxoethyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




10667188

PAGE 2-A




RN 676351-64-7 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[[1-[3-(4-morpholinyl)-3-oxopropyl]-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A




RN 676351-65-8 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-[2-[4-(1,1-dimethylethyl)phenyl]ethyl]-4-piperidinyl)methyl]-2-ethyl- (9CI) (CA INDEX NAME)



RN 676351-66-9 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[[1-[2-
[(methylsulfonyl)amino]ethyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX
NAME)



RN 676351-67-0 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(2-hydroxy-
3,3-dimethylbutyl)-4-piperidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)

10667188



RN 676351-68-1 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[[1-(2-hydroxybutyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 676351-69-2 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[[1-(2-hydroxybutyl)-4-piperidinyl]methyl]-, ethanedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 676351-68-1

CMF C20 H30 Cl N5 O2


10667188



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 676351-70-5 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[[1-(2-hydroxy-2-methylpropyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 676351-71-6 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(2-hydroxy-2-methylpropyl)-4-piperidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)

10667188




RN 676351-72-7 CAPLUS
 CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-[(2R)-3-hydroxy-2-methylpropyl]-4-piperidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 676351-73-8 CAPLUS
 CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-methyl-N-[[1-(1,3,3-trimethyl-2-oxobutyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



10667188

RN 676351-74-9 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-methyl-N-[[1-[2-(1-methylcyclopropyl)-2-oxoethyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 676351-75-0 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-methyl-N-[[1-[(tetrahydro-4-hydroxy-2H-pyran-4-yl)methyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




10667188

PAGE 2-A



RN 676351-76-1 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[[1-
[(tetrahydro-4-hydroxy-2H-pyran-4-yl)methyl]-4-piperidinyl]methyl]- (9CI)
(CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 676351-77-2 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(2-hydroxy-
1,1-dimethylethyl)-4-piperidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



10667188

RN 676351-78-3 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-methyl-N-[[1-
[(tetrahydro-2H-pyran-4-yl)methyl]-4-piperidiny]methyl]- (9CI) (CA INDEX
NAME)

PAGE 1-A



PAGE 2-A




IT 519147-99-0P 676322-53-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of N-(piperidin-4-ylmethyl) imidazopyridinecarboxamides as
5-HT4 receptor modulators)


RN 519147-99-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(5-amino-6-chloro-2-ethylimidazo[1,2-
a]pyridin-8-yl)carbonyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA
INDEX NAME)



10667188

RN 676322-53-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[(5-amino-6-chloro-2-methylimidazo[1,2-a]pyridin-8-yl)carbonyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:335105 CAPLUS
DN 138:353992
TI Preparation of imidazopyridines as 5-HT₄ receptor modulators
IN Fenwick, David Roy; Gymer, Geoffrey Edward; Noguchi, Hirohide; Stobie, Alan; Uchida, Chikara
PA Pfizer Pharmaceuticals Inc., Japan; Pfizer Inc.
SO PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003035649	A1	20030501	WO 2002-IB4098	20021003
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2003092699	A1	20030515	US 2002-251109	20020920
	US 6624162	B2	20030923		
	US 2004034226	A1	20040219	US 2003-617920	20030710
PRAI	US 2001-343371P	P	20011022		
	US 2002-412485P	P	20020920		
	US 2002-251109	A3	20020920		
OS	MARPAT 138:353992				
GI					

10667188



AB Title compds. [I; R1 = H, halo, alkyl; R2, R3 = H, alkyl, alkenyl, alkynyl, aminoalkyl, hydroxyalkyl; R2R3N = (substituted) heterocyclyl; R4 = H, halo, acyl, amino, amido, aryl, arylalkyl, heteroaryl; R5 = H, halo, alkyl, alkenyl, alkynyl, acyl, amino, amido, aryl, arylalkyl, heteroaryl; R6 = H, alkyl, alkoxyalkyl; X = NR9 wherein R9 = H or alkyl; and Y = (CR7R8)n; n = 0-5], were prepared for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome, etc. (no data). Thus, Et 5-amino-6-chloroimidazo[1,2-a]pyridine-8-carboxylate (preparation given) was stirred 20 min. with carbonyldiimidazole; 1-(1-butyl-4-piperidinyl)methanamine and Et3N were added followed by stirring overnight to give 40% 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-6-chloroimidazo[1,2-a]pyridine-8-carboxamide.


IT **519147-78-5P 519147-80-9P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of imidazopyridines as 5-HT4 receptor modulators)

RN 519147-78-5 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-6-chloro-2-methyl- (9CI) (CA INDEX NAME)



RN 519147-80-9 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(3-methoxypropyl)-4-piperidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)

10667188




IT 519148-31-3P 519148-32-4P 519148-33-5P
519148-34-6P 519148-36-8P 519148-37-9P
519148-40-4P 519148-41-5P 519148-48-2P
519148-50-6P 519148-51-7P 519148-52-8P
519148-53-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazopyridines as 5-HT4 receptor modulators)

RN 519148-31-3 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-2-ethyl- (9CI) (CA INDEX NAME)



RN 519148-32-4 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-3-chloro-2-ethyl- (9CI) (CA INDEX NAME)

10667188




RN 519148-33-5 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[[1-(3-methoxypropyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 519148-34-6 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-2-ethyl-N-[[1-(3-methoxypropyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




10667188

RN 519148-36-8 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidiny)methyl]-6-chloro-2-propyl-, mono(4-methylbenzenesulfonate)
(9CI) (CA INDEX NAME)


CM 1

CRN 519148-02-8
CMF C21 H32 Cl N5 O




CM 2

CRN 104-15-4
CMF C7 H8 O3 S




RN 519148-37-9 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidiny)methyl]-2-propyl- (9CI) (CA INDEX NAME)



10667188


RN 519148-40-4 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-6-chloro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 519148-41-5 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 519148-48-2 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-methyl-N-[[1-(2-methylpropyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)

10667188




RN 519148-50-6 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-2-methyl-N-[[1-(2-methylpropyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 519148-51-7 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(3,3-dimethylbutyl)-4-piperidinyl]methyl]-2-ethyl- (9CI) (CA INDEX NAME)



10667188


RN 519148-52-8 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[[1-(2-methoxy-2-methylpropyl)-4-piperidiny]methyl]- (9CI) (CA INDEX NAME)



RN 519148-53-9 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(2-methoxy-2-methylpropyl)-4-piperidiny]methyl]-2-methyl- (9CI) (CA INDEX NAME)



IT 519147-97-8P 519147-98-9P 519147-99-0P

519148-02-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of imidazopyridines as 5-HT4 receptor modulators)

RN 519147-97-8 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidiny]methyl)-6-chloro-2-ethyl- (9CI) (CA INDEX NAME)

10667188




RN 519147-98-9 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[[1-(3-methoxypropyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 519147-99-0 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[[(5-amino-6-chloro-2-ethylimidazo[1,2-a]pyridin-8-yl)carbonyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



10667188

RN 519148-02-8 CAPIUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidiny)methyl]-6-chloro-2-propyl- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT